Document is current
Any future updates will be listed below
-
Authors
Tie, Jeanne https://orcid.org/0000-0001-9244-2057
Wang, Yuxuan
Lo, Serigne N. https://orcid.org/0000-0001-5092-5544
Lahouel, Kamel https://orcid.org/0000-0002-4339-5749
Cohen, Joshua D. https://orcid.org/0000-0003-1158-5668
Wong, Rachel https://orcid.org/0000-0002-4926-5689
Shapiro, Jeremy D.
Harris, Samuel J.
Khattak, Adnan
Burge, Matthew E.
Lee, Margaret
Harris, Marion
McLachlan, Sue-Anne
Horvath, Lisa
Karapetis, Christos
Shannon, Jenny
Singh, Madhu
Yip, Desmond
Ananda, Sumitra
Underhill, Craig https://orcid.org/0000-0001-9335-2678
Ptak, Janine
Silliman, Natalie
Dobbyn, Lisa
Popoli, Maria
Papadopoulos, Nickolas https://orcid.org/0000-0001-7135-7451
Tomasetti, Cristian https://orcid.org/0000-0003-3277-4804
Kinzler, Kenneth W.
Vogelstein, Bert https://orcid.org/0000-0003-0766-3854
Gibbs, Peter
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1085531, APP1085531)
Eastern Health Research Foundation
John Templeton Foundation
U.S. Department of Health & Human Services | National Institutes of Health (CA62924, CA009071, GM136577 and CA06973)
- License Information
-
More Information
Article History
Received: 27 July 2024
Accepted: 7 February 2025
First Online: 7 March 2025
Competing interests
: J.T. served as an advisor/consultant for Haystack Oncology, Amgen, Novartis, AstraZeneca, Merck Serono, Merck Sharp & Dohme, Beigene, Pierre Fabre, Bristol Myers Squibb, Gilead, Roche, Takeda and Daiichi Sankyo and reports funding to their institution from Pfizer, Roche, Grail, Pierre Fabre, Daiichi Sankyo, Zentalis, AstraZeneca and GSK. Y.W. is a consultant for Exact Sciences and Belay Diagnostics. B.V., K.W.K. and N.P. are founders of Thrive Earlier Detection, an Exact Sciences Company. K.W.K. and N.P. are consultants to Thrive Earlier Detection. B.V., K.W.K. and N.P. hold equity in Exact Sciences. N.P. is a consultant to Thrive Earlier Detection. B.V., K.W.K., J.D.C. and N.P. are founders of and own equity in Haystack Oncology and ManaT Bio. K.W.K. and N.P. are consultants to Neophore. K.W.K., B.V. and N.P. hold equity in and are consultants to CAGE Pharma. B.V. is a consultant to and holds equity in Catalio Capital Management. The companies named above, as well as other companies, have licensed previously described technologies related to the work described in this paper from Johns Hopkins University. B.V., K.W.K. and N.P. are inventors on some of these technologies. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors and to Johns Hopkins University. Patent applications on the work described in this paper may be filed by Johns Hopkins University. The terms of all these arrangements are being managed by Johns Hopkins University in accordance with its conflict-of-interest policies. Under a license agreement between Exact Sciences and the Johns Hopkins University, C.T. and the University are entitled to royalty distributions. C.T. has patent applications for intellectual property related to cancer early detection, is a member of the Scientific Advisory Board of PrognomiQ and an advisor for Haystack Oncology, and is also a paid consultant for the Rising Tide Foundation and Bayer AG. P.G. is a consultant to Haystack Oncology. The other authors declare no competing interests.
